3 Smartest Dividend Stocks to Buy Now
When the market entered a correction in February and March,…
Sell
7
DNMR Quote, Financials, Valuation and Earnings
Last price:
$0.35
Seasonality move
:
-23.63%
Day range:
$0.35 - $0.35
52-week range:
$0.33 - $47.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.03x
P/B ratio:
0.01x
Volume:
--
Avg. volume:
14.3K
1-year change:
-99.2%
Market cap:
$1.1M
Revenue:
$46.7M
EPS (TTM):
-$40.80
Analysts' Opinion
-
Consensus RatingDanimer Scientific has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.00, Danimer Scientific has an estimated upside of 1185.71% from its current price of $0.35.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.50 representing 100% downside risk from its current price of $0.35.
Fair Value
-
According to the consensus of 2 analysts, Danimer Scientific has 1185.71% upside to fair value with a price target of $5.00 per share.
DNMR vs. S&P 500
-
Over the past 5 trading days, Danimer Scientific has overperformed the S&P 500 by 1.79% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Danimer Scientific does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Danimer Scientific revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Danimer Scientific reported revenues of $8.6M.
Earnings Growth
-
Danimer Scientific has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Danimer Scientific reported earnings per share of -$7.20.
Enterprise value:
366.8M
EV / Invested capital:
--
Price / LTM sales:
0.03x
EV / EBIT:
--
EV / Revenue:
9.80x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-5.11x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$26.9M
Return On Assets:
-16.27%
Net Income Margin (TTM):
-297.1%
Return On Equity:
-43.3%
Return On Invested Capital:
-17.3%
Operating Margin:
-217.34%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $55.6M | $51.1M | $37.4M | $10.9M | $8.6M | |
| Gross Profit | -$10M | -$23.3M | -$26.9M | -$7.7M | -$7.3M | |
| Operating Income | -$129.5M | -$124.1M | -$86.9M | -$31.2M | -$18.8M | |
| EBITDA | -$106.3M | -$94.2M | -$52.1M | -$24M | -$11.4M | |
| Diluted EPS | -$64.80 | -$56.40 | -$40.80 | -$15.60 | -$7.20 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $238.9M | $162.6M | $127.1M | $69.9M | |
| Total Assets | -- | $650.2M | $733.4M | $721M | $643.8M | |
| Current Liabilities | -- | $32.5M | $31.6M | $14.8M | $21.3M | |
| Total Liabilities | -- | $121.2M | $341.7M | $416.7M | $432.2M | |
| Total Equity | -- | $529.1M | $391.7M | $304.3M | $211.6M | |
| Total Debt | -- | $29.9M | $287.5M | $379.9M | $387.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$73.1M | -$35.6M | -$62.4M | -$10.2M | -$14.5M | |
| Cash From Investing | -$240.2M | -$56.6M | -$8.3M | -$2.7M | -$2.5M | |
| Cash From Financing | $217.8M | $83.2M | $15.1M | -$541K | -$1.1M | |
| Free Cash Flow | -$295.3M | -$92.2M | -$71.8M | -$12.9M | -$18.2M | |
DNMR
Sector
Market Cap
$1.1M
$18.4M
Price % of 52-Week High
0.74%
60.93%
Dividend Yield
0%
0%
Shareholder Yield
-12.31%
1.21%
1-Year Price Total Return
-99.2%
-12.67%
Beta (5-Year)
--
0.927
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.35
200-day SMA
Sell
Level
$10.97
Bollinger Bands (100)
Sell
Level
0.03 - 6.93
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$0.78
Relative Strength Index (RSI14)
Sell
Level
23.69
ADX Line
Neutral
Level
Williams %R
Buy
Level
-97.2973
50-day SMA
Sell
Level
$1.15
MACD (12, 26)
Buy
Level
0.10
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Neutral
Level
--
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.1271)
Sell
CA Score
(Annual)
Level (-1.4015)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (2.4081)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Danimer Scientific Inc creates more sustainable, more natural ways to make plastic products sold under the proprietary Nodax brand name. The company's renewable and sustainable biopolymers have helped create plastic products that are biodegradable and compostable. Danimer Scientific's products return to nature instead of polluting lands and waters. Its technology can be found in a vast array of plastic end-use products that people use every day. Applications for its biopolymers include additives, aqueous coatings, fibers, filaments, films, and injection-molded articles, among others. Geographically, the company generates a majority of its revenue from the United States and the rest from Germany, Poland, Belgium, and other regions.
Stock Forecast FAQ
In the current month, DNMR has received 0 Buy ratings 2 Hold ratings, and 0 Sell ratings. The DNMR average analyst price target in the past 3 months is $5.00.
-
Where Will Danimer Scientific Stock Be In 1 Year?
According to analysts, the consensus estimate is that Danimer Scientific share price will rise to $5.00 per share over the next 12 months.
-
What Do Analysts Say About Danimer Scientific?
Analysts are divided on their view about Danimer Scientific share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Danimer Scientific is a Sell and believe this share price will drop from its current level to $4.50.
-
What Is Danimer Scientific's Price Target?
The price target for Danimer Scientific over the next 1-year time period is forecast to be $5.00 according to 2 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is DNMR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Danimer Scientific is a Hold. 2 of 2 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of DNMR?
You can purchase shares of Danimer Scientific via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Danimer Scientific shares.
-
What Is The Danimer Scientific Share Price Today?
Danimer Scientific was last trading at $0.35 per share. This represents the most recent stock quote for Danimer Scientific. Yesterday, Danimer Scientific closed at $0.35 per share.
-
How To Buy Danimer Scientific Stock Online?
In order to purchase Danimer Scientific stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Could IBIT Go?
Recently, a surprising number of billionaire hedge fund managers have…
Is Raymond James Stock a Buy, Sell or Hold?
Raymond James Financial (NYSE:RJF) is one of America’s large financial…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.6T
P/E Ratio: 37x
Alerts
Buy
80
CORT alert for Apr 1
Corcept Therapeutics [CORT] is down 15.25% over the past day.
Sell
16
PCVX alert for Apr 1
Vaxcyte [PCVX] is down 2.01% over the past day.
Sell
47
RGC alert for Apr 1
Regencell Bioscience Holdings [RGC] is down 3.23% over the past day.
